Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Renee P. Tannenbaum

At a glance: Renee P. Tannenbaum is Director at Ani Pharmaceuticals (ANIP). Their latest SEC Form 4, filed Dec 9, 2025, reported a sale of $146K. On file: 0 purchase lines ($0) and 1 sale line ($146K).

Disclosed holdings: about $1.7M of ANIP stock: 25,157 shares reported on their latest Form 4 (filed Dec 9, 2025), valued at the Nov 20, 2026 close of $69.11. This counts only ANIP shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Ani Pharmaceuticals Inc (ANIP)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $146K

Renee P. Tannenbaum's InsiderPrint

4 trades from SEC Form 4 filings, 2021 to 2025, drawn as one fingerprint.

InsiderPrint of Renee P. Tannenbaum: 4 trades, 2021 to 20252021: 1 buy, 0 sales2022: 1 buy, 0 sales2023: 0 buys, 0 sales2024: 1 buy, 0 sales2025: 0 buys, 1 sale

Reading this print: Mostly buys, trading about once a year, typically $85K a trade.

  • Bump outward: a purchase (3)
  • Dent inward: a sale (1)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Eric EtchartDirector · GGG · 100% match
  2. Justin KassPm · ACV · 100% match
  3. David J. LeeDirector · ZVIA · 99% match
  4. Devin Ignatius MurphyDirector · CXW · 99% match
  5. Dennis V. ArriolaDirector · CMC · 99% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2024

From the SEC's insider data sets: each open-market buy by Renee P. Tannenbaum, matched to how the stock did over the next 90 days against the S&P 500.

0 of 1 buy beat the S&P 500 (0%), median -11.6% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
CRDFDec 18, 2024-11.6%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Dec 9SEC ANIPAni Pharmaceuticals Inc Sell 1,80025,157 held (−7%) $81.15 $146K -14.8%

Follow Renee P. Tannenbaum

Get one email when Renee P. Tannenbaum files a new purchase or sale. Free.

At most one email a day about Renee P. Tannenbaum, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.